PARIS--(BUSINESS WIRE)--Regulatory News:
OSE Pharma SA (ISIN: FR0012127173; Ticker: OSE) (Paris:OSE), an immuno-oncology company developing a T-specific immunotherapy, currently in a registration Phase 3 study, announces that Chief Executive Officer, Dominique Costantini, will share her expertise and experience in the clinical development of anticancer therapies by participating in the workshop, “Phase I: An inflection point in drug development and value generation,” at the BIO-Europe Spring® 2016 Conference, to be held in Stockholm, Sweden, from 4-6 April 2016.
The workshop will take place on Tuesday 5 April between 2:00 – 3:30pm in Room E4 (Level 0) at the Kistamässan Convention Center.
Speakers:
- Jean-Pierre Armand – Senior Oncologist, Expert in Phase I/II, Gustave Roussy Institute
- Jeffrey Yachnin – Clinical Trials Unit, Department of Oncology, Karolinska University Hospital
Moderator:
Mark Nuttall – VP, Business Development and Licensing, Neuroscience, Janssen Business Development
Panelists:
- Martin Bonde – CEO, Vaccibody
- Johan Christenson – Partner, HealthCap
- Dominique Costantini – CEO, OSE Pharma
- Loïc Vincent – Head, Oncology External Innovation, Sanofi
Information relating to the workshop:
- Date: Tuesday 5 April
- Time: 2:00 – 3:30pm
- Location: Room E4 Level 0, Kistamässan Convention Center, Arne Beurlings Torg 5, Stockholm
For more information: http://www.ebdgroup.com/bes/program/index.php
ABOUT BIO-Europe Spring®
BIO-Europe Spring® is the premier springtime partnering conference which annually attracts an international "who's who" from biotech, pharma and finance for three days of high caliber networking taking place in Stockholm from 4-6 April 2016.
Featuring EBD Group's sophisticated partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.
ABOUT OSE PHARMA
OSE Pharma is a biotechnology company that designs and develops cancer immunotherapy treatments aimed at re-educating the immune system to fight cancer while preserving patients’ quality of life.
On February 24, 2016, OSE Pharma and Effimune announced a proposed merger to create significant immunotherapy player. The objective of the merger is to create a new international enterprise that offers innovative immunotherapies based on the activation or regulation of the immune system. This new generation of products is optimized to better target key receptors of the activation or regulation of immune response and allow a durable therapeutic effect. The new company will benefit from a balanced portfolio that would open up major avenues to growth and have a financial visibility of about two years to advance its projects toward greater attractiveness.
OSE Pharma is currently conducting a Phase 3 registration trial in Europe and the U.S. for its lead product, Tedopi®, in the treatment of NSCLC.
Tedopi® (OSE-2101) is a new “off-the-shelf” cancer immunotherapy approach based on OSE Pharma’s proprietary Memopi® technology. This technology is based on “neo-epitopes” (small synthetic peptides chemically modified to increase the binding the HLA A2 or TCR receptors) which activate a cytotoxic T-cell response and leads the immune system to destroy cancer cells. More than 10,000 epitopes were selected to obtain a therapeutic universal T vaccine.
Tedopi® combines 10 optimized “neo-epitopes” simultaneously acting against 5 tumor-associated antigens (TAAs). These 5 antigens have been selected because they are a factor of poor prognosis in several types of cancers. The 10 “neo-epitopes” have been selected and modified to enhance their binding to HLA-A2 and TCR receptors, and trigger a stronger cytotoxic T-cell response and lead the immune system to destroy cancer cells expressing the HLA-A2 antigen or one of the targeted cancer antigens.
Tedopi® can also be developed in Phase 2 in combination with other immunotherapeutic products or targeted therapies. It is also considered for other oncology indications (ovary, colon, breast) for HLA-A2 positive patients.
OSE Pharma is listed on Euronext Paris (ISIN: FR0012127173; Mnémo: OSE).
For more information, please visit www.osepharma.com.
Follow us on Twitter @OSE_Pharma
Disclaimer:
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE PHARMA. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE PHARMA’s management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
Forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.
Although the OSE PHARMA’s management believes that the forward-looking statements and information are reasonable, the OSE PHARMA’s shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE PHARMA. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE PHARMA with the AMF. Such forward-looking statements are not guarantees of future performance.
This press release includes only summary information and should be read with the OSE PHARMA Reference Document filed with the AMF on 12 June 2015 under the number R.15-051 as well as the consolidated financial statements and the management report for the fiscal year 2015, available on the OSE PHARMA website.
OSE PHARMA undertakes no obligation to update any forward-looking statements except what would be required by applicable laws and regulations.